Idiopathic Pulmonary Fibrosis

Pulmonary fibrosis is characterized by the gradual thickening or scarring of tissue deep in the lungs, and is classified as idiopathic if the specific cause is unidentifiable. Idiopathic pulmonary fibrosis (IPF) is the most common of approximately 200 interstitial lung diseases that cause alveolar scarring in the lungs. The resulting fibrosis leads to an irreversible reduction in oxygen flow in the bloodstream.

Middle-aged and older adults are more commonly diagnosed with IPF than younger patients. The disease has variable progression rates, with most patients living 3-5 years after diagnosis. Causes of the disease can vary widely, and can include airborne toxins, some lung diseases, or certain types of medical treatments such as radiation therapy. Some cases of IPF can also be linked to genetic history.

Complications related to IPF include respiratory failure, pulmonary hypertension or embolism, pneumonia, heart failure and lung cancer. According to the Coalition for Pulmonary Fibrosis, IPF is 5 times more common than cystic fibrosis and Lou Gehrig’s Disease (ALS), affecting more than 128,000 people in the United States and resulting in death rates similar to those from breast cancer. Typical treatment includes anti-inflammatory drugs, oxygen supplementation, and lung transplantation.

Novare research suggests that treating IPF patients with Novare RHAMM-blocking peptides can:

  • Reduce pulmonary inflammation
  • Prevent lung fibrosis

For more information on the research, view Novare videos and peruse research articles.

100 High St., 28th Floor
Boston, MA 02110
This email address is being protected from spambots. You need JavaScript enabled to view it.